Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
Aligos Therapeutics (Nasdaq: ALGS) announced six preclinical presentations at the 2025 International HBV Meeting in Berlin, including three oral presentations. The presentations showcase the company's research in liver and viral diseases, particularly focusing on ALG-000184 and a new antisense oligonucleotide (ASO) approach for hepatitis delta virus (HDV) treatment.
Key highlights include the first presentation of ALG-000184's direct effects in reducing HBV cccDNA in preclinical settings, supporting clinical observations of HBV antigen reductions in patients. Additionally, the company is expanding its pipeline with an ASO program for HDV treatment, targeting viral genome destruction as a potential cure strategy for HDV coinfection, which typically leads to more rapid disease progression.
Aligos Therapeutics (Nasdaq: ALGS) ha presentato sei comunicazioni precliniche al 2025 International HBV Meeting di Berlino, di cui tre orali. Le presentazioni illustrano le ricerche dell'azienda sulle malattie epatiche e virali, con particolare attenzione ad ALG-000184 e a un nuovo approccio con oligonucleotidi antisenso (ASO) per il trattamento dell'epatite delta (HDV).
Tra i punti salienti, la prima dimostrazione degli effetti diretti di ALG-000184 nella riduzione del cccDNA dell'HBV in modelli preclinici, a sostegno delle osservazioni cliniche di diminuzione degli antigeni HBV nei pazienti. Inoltre, l'azienda sta ampliando la pipeline con un programma ASO per l'HDV, mirato alla distruzione del genoma virale come possibile strategia di cura per la coinfezione HDV, nota per un decorso di malattia più rapido.
Aligos Therapeutics (Nasdaq: ALGS) anunció seis presentaciones preclínicas en el 2025 International HBV Meeting en Berlín, incluidas tres orales. Las ponencias muestran la investigación de la compañía en enfermedades hepáticas y virales, con énfasis en ALG-000184 y un nuevo enfoque con oligonucleótidos antisentido (ASO) para el tratamiento de la hepatitis delta (HDV).
Entre los puntos destacados figura la primera demostración de los efectos directos de ALG-000184 en la reducción del cccDNA del VHB en modelos preclínicos, respaldando las observaciones clínicas de reducción de antígenos del VHB en pacientes. Además, la empresa está ampliando su cartera con un programa ASO para HDV, orientado a destruir el genoma viral como posible estrategia curativa para la coinfección por HDV, que suele acelerar la progresión de la enfermedad.
Aligos Therapeutics (Nasdaq: ALGS)는 2025년 베를린에서 열린 International HBV Meeting에서 구두 발표 3건을 포함한 6건의 전임상 발표를 발표했습니다. 이들 발표는 간 및 바이러스성 질환 분야에서의 회사 연구를 보여주며, 특히 ALG-000184와 HDV(델타간염바이러스) 치료를 위한 새로운 안티센스 올리고뉴클레오타이드(ASO) 접근법에 중점을 둡니다.
주요 내용으로는 전임상 모델에서 ALG-000184가 HBV cccDNA를 직접 감소시키는 효과가 처음으로 보고되어, 환자에서 관찰된 HBV 항원 감소 임상 결과를 뒷받침했습니다. 또한 회사는 HDV 동반감염에 대한 잠재적 치료 전략으로 바이러스 게놈 파괴를 목표로 하는 HDV용 ASO 프로그램으로 파이프라인을 확장하고 있습니다. HDV 동반감염은 일반적으로 질병 진행이 더 빠릅니다.
Aligos Therapeutics (Nasdaq: ALGS) a annoncé six présentations précliniques lors de l'International HBV Meeting 2025 à Berlin, dont trois présentations orales. Ces communications mettent en avant la recherche de la société sur les maladies hépatiques et virales, en se concentrant notamment sur ALG-000184 et une nouvelle approche par oligonucléotides antisens (ASO) pour le traitement de l'hépatite delta (HDV).
Parmi les points clés figure la première démonstration des effets directs d'ALG-000184 sur la réduction de l'cccDNA du VHB en contextes précliniques, soutenant les observations cliniques de diminutions des antigènes VHB chez les patients. De plus, la société étend son portefeuille avec un programme ASO pour l'HDV, visant à détruire le génome viral comme stratégie potentielle de guérison pour la co-infection par l'HDV, qui entraîne généralement une progression plus rapide de la maladie.
Aligos Therapeutics (Nasdaq: ALGS) kündigte sechs präklinische Präsentationen auf dem International HBV Meeting 2025 in Berlin an, davon drei Vorträge. Die Beiträge zeigen die Forschung des Unternehmens zu Leber- und Viruskrankheiten, mit besonderem Fokus auf ALG-000184 und einen neuen Antisense-Oligonukleotid-(ASO)-Ansatz zur Behandlung der Hepatitis-Delta-Virus (HDV)-Infektion.
Wesentliche Höhepunkte sind die erste Darstellung der direkten Wirkung von ALG-000184 zur Reduktion des HBV-cccDNA in präklinischen Modellen, was klinische Beobachtungen einer Verringerung von HBV-Antigenen bei Patienten stützt. Darüber hinaus erweitert das Unternehmen seine Pipeline um ein ASO-Programm für HDV, das auf die Zerstörung des viralen Genoms als mögliche Heilungsstrategie bei HDV-Koinfektionen abzielt, die meist zu einem schnelleren Krankheitsverlauf führen.
- None.
- None.
Insights
Aligos' preclinical data validates ALG-000184's mechanism against HBV and introduces promising HDV therapy, strengthening their antiviral portfolio.
The six presentations scheduled for the 2025 International HBV Meeting provide important validation for Aligos Therapeutics' development programs, particularly for their lead asset ALG-000184. The most significant revelation is preclinical data demonstrating that ALG-000184 can directly reduce hepatitis B virus (HBV) cccDNA, which represents a crucial validation of its secondary mechanism as a capsid assembly modulator effector (CAM-E). This mechanistic confirmation supports the clinical observations of HBV antigen reductions seen in patients treated with ALG-000184 monotherapy.
The company is also expanding beyond HBV with a new antisense oligonucleotide (ASO) approach targeting hepatitis delta virus (HDV), a serious coinfection that accelerates liver disease progression. This strategy is particularly noteworthy as it aims to directly destroy the viral genome, potentially offering a curative approach to HDV - an area with significant unmet medical need.
The multiple presentations across both oral and poster formats suggest Aligos is making coordinated progress in understanding the molecular mechanisms of their therapeutic approaches. The company's Phase 2 B-Supreme study for ALG-000184 is reportedly progressing well, while preclinical work continues toward selection of a clinical development candidate for the HDV program. The data collectively strengthens Aligos' scientific positioning in antiviral therapeutics targeting the liver, particularly for difficult-to-treat viral infections where existing treatment options are limited or suboptimal.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 – 12, 2025 in Berlin, Germany.
The company and its collaborators’ commitment to advancing next-generation therapies for liver and viral diseases is reflected in these presentations, with topics spanning novel approaches, molecular strategies, insights into the mechanisms of action of ALG-000184, as well as a new strategy to potentially cure hepatitis delta virus (HDV) infection utilizing a proprietary antisense oligonucleotide (ASO) approach.
“We are pleased to present six preclinical presentations at the International HBV Meeting, that showcase our continued innovation in liver and viral diseases. With the Phase 2 B-Supreme study progressing nicely, we are pleased to present, for the first time, the direct effects of ALG-000184 in reducing HBV cccDNA in a preclinical setting. These data help corroborate the clinical observations of HBV antigen reductions seen in patients with chronic HBV infection treated with ALG-000184 monotherapy to date and are a direct indication that ALG-000184 can invoke the secondary mechanism of CAM-Es,” stated Lawrence Blatt, PhD, MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “While we remain committed to the continued development of our best/first-in-class CAM-E ALG-000184 for chronic HBV infection, we are pleased to broaden our pipeline with the presentation of our discovery stage ASO program for the treatment of HDV. HDV coinfection with HBV leads to more rapid disease progression and our ASO uniquely targets the destruction of the viral genome, making this mechanism uniquely suited towards a potential HDV cure. Ongoing work will be aimed at selection of the HDV-targeted ASO clinical development candidate.”
Details on the presentations are as follows:
Paper #: 52
Type: Oral Presentation
Title: The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments
Presenter: Yannick Debing, PhD
Date/Time: September 11, 2025 at 10:30am – 12:00pm CET
Session: Session X: Therapy II
Paper #: 53
Type: Oral Presentation
Title: Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
Presenter: Julie Lucifora, PhD, CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon
Date/Time: September 11, 2025 at 10:30am – 12:00pm CET
Session: Session X: Therapy II
Paper #: 2
Type: Oral Presentation
Title: A Syrian hamster model of persistent HDV infection
Presenter: Elias Broeckhoven, KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute; Virology, Antiviral Drug and Vaccine Research Group; Laboratory of Molecular Vaccinology & Vaccine Discovery (MVVD)
Date/Time: September 8, 2025 at 5:00pm – 6:30pm CET
Session: Molecular Virology I
Paper #: 283
Type: Poster Presentation
Title: Differential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitro
Presenter: Hannah Vanrusselt
Date/Time: September 10, 2025 at 11:00am – 12:00pm CET
Session: Poster Session II
Paper #: 285
Type: Poster Presentation
Title: Capsid assembly modulators bind and directly target HBeAg
Presenter: Jordi Verheyen
Date/Time: September 10, 2025 at 11:00am – 12:00pm CET
Session: Poster Session II
Paper #: 127
Type: Poster Presentation
Title: PML nuclear bodies store aggregated HBc and reduce CAM-induced apoptosis in HBc-expressing cells
Presenter: Vaclav Janovec, PhD, University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
Date/Time: September 8, 2025 at 5:00pm – 6:30pm CET
Session: Molecular Virology
The presentations can be found on the Posters & Presentations section of the Aligos website (www.aligos.com) after the live event.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com
FAQ
What are the key presentations announced by Aligos Therapeutics (ALGS) for the 2025 International HBV Meeting?
What new data is Aligos (ALGS) presenting about ALG-000184?
How is Aligos Therapeutics (ALGS) approaching HDV treatment?
When and where is Aligos (ALGS) presenting at the International HBV Meeting 2025?
